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a b s t r a c t
Using p53 to drive transgene expression from viral vectors may provide on demand expression in
response to physiologic stress, such as hypoxia or DNA damage. Here we introduce AAVPG, an adeno-
associated viral (AAV) vector where a p53-responsive promoter, termed PG, is used to control transgene
expression. In vitro assays show that expression from the AAVPG-luc vector was induced speciﬁcally in the
presence of functional p53 (10387202 fold increase, po0.001). The AAVPG-luc vector was an effective
biosensor of p53 activation in response to hypoxia (4.4870.6 fold increase in the presence of 250 mM CoCl2,
po0.001) and biomechanical stress (2.5370.4 fold increase with stretching, po0.05). In vivo, the vigilant
nature of the AAVPG-luc vector was revealed after treatment of tumor-bearing mice with doxorubicin (pre-
treatment, 3.410570.43105 photons/s; post-treatment, 6.610572.1105 photons/s, po0.05). These
results indicate that the AAVPG vector is an interesting option for detecting p53 activity both in vitro and in vivo.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Innumerous studies have shown that the tumor suppressor p53
plays a central role in the cellular response to a variety of
physiological stimuli. p53 is typically thought of as a master
regulator of the cell cycle arrest and cell death due its ability to
activate or repress the expression of critical target genes upon
DNA damage (Beckerman and Prives, 2010). However, p53 func-
tion is much more complex due to the large number of factors that
can lead to p53 activation as well as the variety of physiological
outcomes that it mediates.
Findings implicate p53 function extends to metabolism (Bensaad
et al., 2006) autophagy (Crighton et al., 2006; Ravikumar et al., 2010)
and regulation of microRNA expression (Hermeking, 2007; Junttila
and Evan, 2009). In addition to ionizing radiation (Hildesheim et al.,
2002; Klokov et al., 2012; Rashi-Elkeles et al., 2011), p53 activity can
also be induced by oncogenic stress (Feng et al., 2006; Yan et al., 2005),
oxidative stress (Achanta and Huang, 2004; Sinthupibulyakit et al.,
2010), signaling cytokines (Doman et al., 1999; Kim et al., 2005),
changes in temperature (Bajgelman and Strauss, 2006; Michalovitz
et al., 1990; Zhang et al., 1994), hypoxia (Long et al., 1997; Sano et al.,
2007; Sutton et al., 2008), chemotherapeutic agents (Chuang et al.,
2012; el-Deiry et al., 1994; Lowe et al., 1993; Wang et al., 2005) and
biomechanical stress (Leri et al., 1998, 2000; Liao et al., 2004).
Molecular tools that reveal the activities of p53 would help deepen
our understanding of many cellular processes.
The p53 protein typically functions as a transcription factor
controlling the expression of a variety of target genes in order to
bring about its pleiotropic effects. In general, these genes contain
the canonical p53 binding site (5′–RRRCWWGYYY-3′ where R¼G
or A, W¼T or A, Y¼C or T) in their promoter region (el-Deiry et al.,
1992). One of the ﬁrst p53 responsive elements identiﬁed (referred
to here as the PG element) was derived from the ribosomal gene
cluster (Kern et al., 1991) and, when used to drive reporter gene
expression, was shown to mediate transactivation by wild-type
p53 (Kern et al., 1992). A few examples of p53 target genes include
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p21, GADD45, Mdm-2, and Bax, among others (Barak et al., 1993;
el-Deiry et al., 1992, 1993; Funk et al., 1992; Juven et al., 1993; Kern
et al., 1991, 1992). Since the transcriptional activities of p53 are
central to its function, the expression of p53 target genes can
reveal when and where p53 is called to duty.
We have developed biosensors that reveal p53 activity. These
tools include recombinant viral vectors where transcription of the
gene of interest is controlled by p53. In this way, the viral vector
facilitates gene transfer and the observation of reporter gene
activity can reveal the induction of p53 function. In our ﬁrst
generation vector, the PG element was used to modify LTR of the
pCL retroviral vector (Strauss et al., 2005; Strauss and Costanzi-
Strauss, 2004). The pCLPG retrovirus is especially well suited for
ex vivo laboratory studies due to the biology of retroviral vectors
derived from Moloney Murine Leukemia Virus.
For the second generation of p53-responsive vectors, we turned
to adenovirus (Ad) since these vectors offer high titer, efﬁcient
in situ gene transfer and remain episomal, thus avoiding problems
associated with viral integration. To this end, we developed a
chimeric promoter named PGTxβ, which is a fusion of the p53
responsive PG element (Kern et al., 1991), with the adenovirus E1B
minimal promoter (Xavier-Neto et al., 1998) and a rabbit β-globin
intron (Schambach et al., 2000). This chimeric promoter was
inserted into a recombinant serotype 5 adenoviral vector (termed
AdPG) and used to drive expression of the luciferase reporter gene.
We observed both speciﬁc and high level transgene expression
induced by p53 (Bajgelman and Strauss, 2008). Despite the wide
use of adenovirus for in vivo applications, data from the literature
suggest some drawbacks, such as its immunogenicity and short-
term expression (Alemany et al., 2000; Olive et al., 2002; Worgall
et al., 1997).
Recombinant vectors based on adeno-associated virus (AAV) offer
many features that are desirable in a gene transfer vehicle. AAV vectors
are much less immunogenic than Ad (Li et al., 2007) and provide long
term expression in non-dividing cells (Leger et al., 2011; Rivera et al.,
1999). In addition, it is possible to direct viral tropism to a speciﬁc
tissue by manipulating the serotype or engineering the viral capsid
(Asokan et al., 2012; Li et al., 2007; Palomeque et al., 2007). In situ gene
transfer with AAV vectors is well tolerated and the virus may remain
in the target cell for some time.With the use of a conditional promoter
to drive expression, the vector can be applied even before the physio-
logic condition is manifested, thus providing vigilant, ‘on-demand’
expression of the transgene.
Here we present the development of AAVPG, our third genera-
tion vector where transgene expression is driven by p53. Using
AAVPG encoding luciferase, we show induction of reporter gene
activity ‘on-demand’ in response to several forms of cellular stress
known to activate p53. The AAVPG vigilant vector offers tight
control over transgene expression in response to p53 and, thus,
may serve as a biosensor of p53 activity.
Results
AAVPG-luc expression is tightly regulated by p53
The three generations of p53-responsive vectors are repre-
sented in Fig. 1. The construction of the AAVPG vector began by
inserting sequences to direct site-speciﬁc homologous recombina-
tion in a promoterless AAV2 transfer vector. In parallel, the
chimeric promoter responsive to p53, called PGTxβ (Bajgelman
and Strauss, 2008), and the gene of interest, luciferase, were
inserted in a second plasmid already encoding sequences for site
directed recombination that are compatible with the new AAV2
transfer vector. The ﬁnal vector, AAVPG-luc, was derived by
recombination between the two plasmids.
To explore regulation of expression directed by p53, the H358 cell
line (human lung carcinoma, p53-null) was modiﬁed with the
introduction of a retrovirus encoding the temperature sensitive allele
of human p53 mutant at codon 143 (Strauss et al., 2005). P53(143)
assumes a mutant phenotype when the cells harboring it are
cultivated at 37 1C, yet switches to a transcriptionally active conforma-
tion at 32 1C (Zhang et al., 1994). As seen in Fig. 2, H358(143) cells
transduced with AAVPG-luc (MOI¼100) and cultivated at 32 1C show
a 1000 fold induction of reporter activity over cells cultivated at 37 1C.
This temperature sensitive induction was not observed in parental
H358 cells, which do not have expression of p53. A slight increase in
reporter activity was observed when AAVCMV-luc was used to
transduce either parental or H358(143) cells which were then
cultivated at 32 1C. This apparent induction is likely non-speciﬁc and
is not strong enough to alter the interpretation of the performance of
the AAVPG-luc vector. When induced, the AAVPG vector provides
transgene activity that is superior to that seen with the AAVCMV
vector, a point that is made clearer when the data is presented with
normalization only for protein content (Fig. S1). This assay shows that
expression of the transgene encoded by the AAVPG vector is speciﬁ-
cally controlled by p53 and that high levels of induction can be
achieved.
AAVPG-luc as a biosensor of chemotherapeutic activity
The use of chemotherapeutic agents such as doxorubicin can
induce the activity of endogenous p53 (el-Deiry et al., 1994). In
this experiment, B16 cells (mouse melanoma, wild-type. p53) were
Fig. 1. Schematic representation of the three generations of p53-responsive viral
vectors. First generation: pCLPG is a recombinant retroviral vector derived from
Moloney murine leukemia virus. The p53-responsive element, PG, was fused with
the viral LTR (substituting the U3 element), thus rendering transgene expression
under the control of p53 (Strauss and Costanzi-Strauss, 2004). Second generation:
AdPG is a serotype 5 adenoviral vector which has a chimeric p53-responsive
promoter, PGTxβ, driving expression of the transgene (Bajgelman and Strauss,
2008). Third generation: AAVPG is a recombinant serotype 2 adeno-associated
virus that contains the PGTxβ promoter driving expression of the transgene.
Construction of AAVPG vectors is aided by site directed recombination at the Att
sequence.
Fig. 2. Robust expression from AAVPG-luc driven by a temperature-sensitive allele of
p53. H358() cells (that lack endogenous expression of p53) and H358(148) cells (that
express a temperature sensitive allele of p53) were transduced with a preparation of
AAVPG-luc or AAVCMV-luc, using MOI of 100, and incubated at 37 1C or 32 1C, as
indicated. Luciferase activity, presented in arbitrary units (au), was normalized by
protein concentration, considering the activity obtained at 37 1C as 1, for the parental
lineage H358(). The graph represents the mean and standard deviation of three
independent experiments wherein each condition was performed in duplicate.
nPo0.001, two-way ANOVA followed by the Bonferroni post hoc test.
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co-transduced with a mixture of viral preparations AAVPG-luc and
AAVCMV-LacZ (serving as an internal control), using a MOI of 30,000,
subjected to treatment with increasing concentrations of doxorubicin.
As seen in Fig. 3, luciferase reporter activity was correlated with the
drug dose. In contrast, we did not ﬁnd a signiﬁcant alteration in LacZ
expression. Treatment of B16 cells with doxorubicin was associated
with the induction of p53-responsive genes p21 and Mdm2 as well as
an altered cell cycle proﬁle (Fig. S2). In this way, the AAVPG-luc vector
served as a biosensor of the induction of p53 by doxorubicin.
The vector AAVPG-luc can be used as a sensor of hypoxia
We next sought to conﬁrm the utility of AAVPG-luc as a reporter of
hypoxia, a condition known to activate p53 (Long et al., 1997; Sano
et al., 2007). In this assay, NIH3T3 cells (immortalized mouse
ﬁbroblast, wild-type p53) were co-transduced with AAVPG-luc along
with AAVCMV-LacZ and treated with cobalt chloride, a hypoxia
mimetic. We found that the addition of cobalt chloride induced a
dose-dependent increase in the reporter gene activity provided by
AAVPG-luc (Fig. 4). In contrast, we found that LacZ activity diminished
in response to the increasing concentrations of cobalt chloride, in
agreement with reports from the literature (Vordermark et al., 2001).
The treatment of NIH3T3 cells with CoCl2 was associated with the
induction of p53-target genes p21 and Mdm2 (Fig. S3). These ﬁndings
suggest a dose-dependent modulation of expression of AAVPG-luc
which we attribute to activation of p53.
Biomechanical stress activates expression from the AAVPG-luc vector
Data from the literature (Leri et al., 1998; Liao et al., 2004) have
suggested that stretching can lead to p53 activation. Here NIH3T3
cells were again co-transduced with AAVPG-luc and AAVCMV-
LacZ, but cultivated in the presence of biomechanical stress
for 24 h. We observed an increase in luciferase activity when
compared with resting (non-stressed) cells, indicating that the
expression from the AAVPG-luc vector was modulated by the
biomechanical stress (Fig. 5). In contrast, there was no change in
LacZ reporter gene activity between resting and stretched cells. In
this ﬁnal example, the AAVPG-luc vector again showed its utility as
a biosensor of p53 activity.
In vivo bioluminescent imaging of AAVPG-luc reveals p53 activity
We next evaluated the potential application of AAVPG as an
in vivo sensor of p53 activity upon induction by doxorubicin. For
this, melanoma-derived B16 cells were transduced ex vivo with
AAV vectors and implanted subcutaneously in syngeneic C57BL/6
mice. In Fig. 6 we show that luciferase activity was increased after
doxorubicin treatment only in the AAVPG-luc group. In contrast,
there was a reduction in luciferase activity in the AAVCMV-luc
group upon drug treatment. This assay demonstrates the vigilant,
bio-sensing role of the AAVPG vector in vivo.
Discussion
In this work we show that our third generation p53-responsive
viral vector can be used as a biosensor of p53 activity in response
to temperature, chemotherapy, hypoxia and mechanical stress. The
PGTxβ promoter, previously described by our group (Bajgelman
and Strauss, 2008), proved to be reliable in the context of an AAV
vector. The AAV vector developed here also offers compatibility
with the Gateway cloning technology, a feature that may facilitate
the construction of vectors containing varied promoters and/or
genes of interest.
As compared to our ﬁrst and second generation vectors (retro-
viral and adenoviral, respectively), the use of an AAV vector offers
Fig. 3. Expression from AAVPG-luc is regulated by endogenous p53 in B16 cells.
Cells were co-transduced with AAVPG-luc and AAVCMV-LacZ, using MOI of 30,000,
incubated 24 h at 37 1C before the media was changed to include the indicated
amounts of doxorubicin (Dox). Cells were harvested 24 h later for analysis of
luciferase activity and β-gal activity. The reporter activities were normalized
considering the sample with transduction, but without drug treatment, as 1 and
presented in arbitrary units (au). nPo0.001, two-way ANOVA followed by the
Bonferroni post hoc test. The graph represents the mean and standard deviation of
three independent experiments wherein each condition was performed in
duplicate.
Fig. 4. Hypoxia activates p53 and induces AAVPG-luc expression. NIH3T3 cells
were co-transduced with a mixture of AAVPG-luc and AAVCMV-LacZ (MOI¼500)
and incubated 24 h. Media was changed, adding the indicated concentration of
cobalt chloride (CoCl2). Cells were harvested after 24 h when luciferase and β-gal
activities were determined. The condition without cobalt chloride was called 1.
nPo0.001, two-way ANOVA followed by the Bonferroni post hoc test. The graph
represents the mean and standard deviation of three independent experiments
wherein each condition was performed in duplicate.
Fig. 5. Biomechanical stress activates p53 and induces AAVPG-luc expression.
NIH3T3 cells were seeded on Bioﬂexs culture plates and co-transduced with
AAVPG-luc and AAVCMV-LacZ, using MOI of 500. After 24 h of 10% stretching, cells
were harvested to quantify luciferase and β-gal expression. The reporter activity in
the absence of stretching was called 1. nPo0.05, two-way ANOVA followed by the
Bonferroni post hoc test. The graph represents the mean and standard deviation of
three independent experiments wherein each condition was performed in
duplicate.
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several improvements, especially with respect to vector biology. For
example, AAV remains predominantly episomal, yet maintains long
term expression, thus avoiding the pitfalls of retroviral integration and
short term adenoviral expression. AAV is also much less immunogenic
than adenovirus, a feature that contributes to the permanence of AAV-
transduced cells in vivo and, as a result, prolongs transgene expression
(Li et al., 2007). In addition, the tropism of AAV vectors can be easily
modiﬁed by pseudotyping with naturally occurring or engineered viral
capsids (Asokan et al., 2012).
AAVPG-luc was tested in different experimental conditions that
are known to activate p53, such as hypoxia and stretching. While
the tumor suppressor functions of p53 are well known, p53 may
also play a critical role mediating the response to physiologic
conditions that are also important for other pathologies. For
example, hypoxia is a common trait of ischemia, such as occurs
in the myocardium upon infarct or uncompensated hypertrophy
(Sano et al., 2007). In another example, biomechanical stress, such
as stretching, is associated with cardiovascular remodeling and is
known to involve the activation of p53 (Leri et al., 1998, 2000).
Even though p53's typical role is related to tumor biology, it also
plays a part in other disease processes. Hence the need for
molecular tools that reveal p53 activity, and thus physiologic
stress, extends to ﬁelds of study beyond cancer.
Interestingly, we were able to use co-transduction of the
AAVPG and AAVCMV vectors and reveal two distinct responses
of viral expression upon induction of stress. Our data show that
there was no crosstalk between the vectors since the measure-
ment of the activity of each reporter gene was reliable and, more
importantly, their responses were distinct. This is an important
point since intermolecular cis activation (where an enhancer
encoded by one AAV vector can inﬂuence gene expression in a
second vector that includes a minimal promoter, but not an
enhancer) has been described (Duan et al., 2000). However, this
was not observed in our studies. Each of our vectors contains a
complete expression cassette and appears not to have been
inﬂuenced by the other vector (i.e., the AAVCMV vector did not
promote expression from the AAVPG vector in the absence of p53
function). Experimental evidence for this will be shown in a
separate study by our group. Therefore, we have shown that two
AAV vectors can be applied together and provide distinct, yet
complimentary, results.
As shown here, the AAVPG vector is an asset for in vivo whole
animal imaging and may even prove to be an interesting vector for
gene therapy. A few reports in the literature have used a similar
approach to measure the role of p53 in the response of tumors to
treatment (Wang and El-Deiry, 2003; Wang et al., 2006). Since p53
is important for other pathologies, the application of AAVPG may
be well suited for in situ gene transfer at the time experimental
surgeries, such as induction of ischemia. Such studies have been
initiated by our group and will be described elsewhere. In this
way, the AAVPG vector may reveal p53 function, but may also
harness p53 activity in order to bring about expression of a
therapeutic transgene.
The AAVPG platform offers several characteristics that are
desirable in a gene transfer vector, such as safety, stability and
expression controlled by p53, a critical sensor and mediator of the
response to physiologic cell stress. We propose that the AAVPG
vector is beneﬁcial for functional assays and represents the ﬁrst
steps in developing a vigilant vector that can provide the expres-
sion of therapeutic transgenes on demand in response to the
activation of p53.
Material and methods
Cell culture and lines
The cell lines 293T, NIH3T3 and B16 were maintained in DMEM
(Gibco-BRL, Grand Island, NY, USA) supplemented with 10% FBS
(HyClone, Logan, UT, USA), 100 mg/ml gentamycin, 50 mg/ml ampi-
cillin, and 2.5 mg/ml fungizone, at 37 1C, in a humidiﬁed atmosphere
of 5% CO2. The cell line H358 was maintained in RPMI-1640 (Gibco-
BRL, Grand Island, NY, USA) supplemented as described above and
maintained in a humidiﬁed atmosphere of 5% CO2, at 37 1C or 32 1C, as
indicated in the experiments.
Vector construction
The AAV Helper-Free System (Stratagene, USA) was modiﬁed to
become compatible with the Gateway site speciﬁc recombination
system and pEntr vectors (Invitrogen Life Technologies). Initially,
we constructed pAAVdest by cloning the recombination site
Fig. 6. Demonstration of the vigilant, bio-sensing role of the AAVPG vector in vivo.
B16 cells were transduced ex vivo with either AAVCMV-luc or AAVPG-luc and
expanded before 5105 cells were implanted subcutaneously in C57BL/6 mice
(n¼5/group). One week later, the animals were subjected to bioluminescence
imaging before i.p. injection of doxorubicin (Dox, 1.5 mg/kg). The animals were
then maintained for 24 h before a second image was captured. n po0.05,
nnn po0.001, one-way ANOVA followed by Tukey's Multiple Comparison test.
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excised from pCDNA/V5-DEST (Invitrogen) into pAAVCMV (Strata-
gene) after removing the CMV promoter/enhancer sequences. To
generate the pEntr vector, we used PCR to amplify the expression
cassette PGTxβ-luc from pAdPG-luc (Bajgelman and Strauss, 2008),
with primers PG-Topo D Forward (5′CACCTCTTTCCCACCCTTAAC-
CAC3′) e PG-Topo D Reverse (5′TAGGCTCAAGCAGTGATCCT3′) and
inserted this into pEntr-D-topo (Invitrogen). Recombination with
pAAV-dest yielded the AAVPG-luc vector. Cloning details can be
provided upon request. AAVCMV-LacZ is a constitutive β-galacto-
sidase reporter vector and was supplied in the AAV Helper-Free
System (Stratagene, USA). AAVCMV-luc was cloned in two steps.
Firstly a 1.4 kb fragment containing a partial 3′ ires element
followed by an eGFP cDNA was cut from p-Ires2-eGFP (Clontech,
USA) with NotI and HindIII, and ligated to AAVCMV-MCS (Strata-
gene, USA). Next, we digested the plasmid vector FE2FLIGfW
(Strauss et al., 2006) with HindIII, to isolate a 2 kb fragment
containing the ﬁreﬂy luciferase reporter gene, followed by a partial
5′ ires element, generating the ﬁnal construct, encoding the luc-
ires-eGFP cassette driven by a CMV promoter.
Preparation of AAV
Viral preparations were produced transiently by co-
transfection of 293T cells with the viral plasmid and serotype
2 packaging plasmids from the AAV Helper-Free System (Strata-
gene-USA). The supernatants and cell lysates were harvested and
virus was puriﬁed using the AAV Puriﬁcation Kit (Cell Biolabs,
USA). Titration was done by qPCR, where a standard curve was
generated using the plasmid form of the AAV vector.
In vitro luciferase and β-gal assay
Cells were treated as indicated in the ﬁgures before being
harvested and lysed in 0.1% Triton X-100, 0.1 M Tris/HCl, pH 8.0 by
a freeze/thaw treatment. The lysate was then clariﬁed by centri-
fugation, 5 min, 10,000 rpm. The supernatant was transferred to a
fresh tube and stored at 20 1C. For luciferase assay, 10 ml of lysate
was added to 50 ml of LAR (Promega, USA), and activity was
measured using a luminometer. Luc activity was normalized by
total protein, measured using Bradford reagent (Bio-Rad, USA). For
the β-galactosidase assay, 30 ml of lysate was added to 100 ml of
ONPG solution (77 ml of 0.1 M Na2HPO4, pH 7.5, 22 ml of 4 mg/ml
ONPG, 1 ml of 0.1 M MgCl2, 4.5 M 2-mercaptoethanol) in a 96 well
plate. The reactions were allowed to proceed for 5 to 15 min, 37 1C,
and stopped using a 1 M sodium carbonate solution. Absorbance
measurements were made at 405 nm using a microtiter plate
reader. Beta gal activity was normalized by total protein, measured
using Bradford reagent (Bio-Rad, USA).
Biomechanical stress
Brieﬂy, 105 NIH3T3 cells/well were seeded on a 6 well Bioﬂexs
culture plate. Cells were incubated at 37 1C for 24 h, transduced
with virus and incubated at 37 1C for additional 24 h. Media was
changed and cells were stretched 10% for 24 h.
In vivo imaging
All experimental procedures followed institutional guidelines
for care and use of laboratory animals, and the protocols were
approved by the Institutional Review Board of the University of
São Paulo School of Medicine (FMUSP), Brazil. Female C57BL/6
mice, 7-weeks old, were obtained from the Centro de Bioterismo,
FMUSP, and housed in the Heart Institute animal facility. Water
and food were supplied ad libitum and the animals' well-being was
monitored closely. All procedures for each experimental group
were performed in parallel such that images and drug treatments
were performed in the same experimental session and in the same
manner, thus minimizing differences in handling.
B16 cells were transduced (MOI¼30,000) ex vivo with either
AAVCMV-luc or AAVPG-luc and expanded before being trypsi-
nized, counted and implanted subcutaneously, 5105 cells in each
C57BL/6 mouse (n¼5/group). After 7 days, when tumors were
palpable, the animals were subjected to bioluminescence imaging
(IVIS Spectrum, Caliper Life Science). For this, the animals received
15 mg/kg of luciferin (Promega) via i.p. injection and, 10 min later,
were anesthetized with isoﬂurane (Cristalia) using the Xenogen
anesthesia system before imaging (performed by Mara de Souza
Junqueira, Centro de Bioterismo, FM-USP). Periodic images were
captured until the luciferin signal dissipated and only the stron-
gest signal was included in the analysis. The animals then received
an i.p. injection of doxorubicin, 1.5 mg/kg, and were maintained for
24-h before repeating the imaging process. Data was analyzed
using Living Imaging 4.3 software (Caliper Life Science). As a
negative control, animals were implanted with B16 cells trans-
duced with the AAVCMV-LacZ vector, resulting in no emission of
photons (data not shown).
Acknowledgments
We thank the laboratories of Dr. José Eduardo Krieger and Dr.
Roger Chammas for their ongoing support and collaboration. This
work was supported by the São Paulo Research Foundation (FAPESP)
in the form of fellowships (MCB 07/54480-2, RFVM 10/03958-2, and
ACPVC 06/56495-7) and grants (BES, 11/50911-4, 07/50210-0) as
well as by the Conselho Nacional de Desenvolvimento Cientíﬁco e
Tecnológico (CNPq) in the form of a grant (MCB 478381/2007-7).
Appendix A. Supplementary Material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2013.09.004.
References
Achanta, G., Huang, P., 2004. Role of p53 in sensing oxidative DNA damage in
response to reactive oxygen species-generating agents. Cancer Res. 64 (17),
6233–6239.
Alemany, R., Suzuki, K., Curiel, D.T., 2000. Blood clearance rates of adenovirus type
5 in mice. J. Gen. Virol. 81 (Pt. 11), 2605–2609.
Asokan, A., Schaffer, D.V., Samulski, R.J., 2012. The AAV vector toolkit: poised at the
clinical crossroads. Mol. Ther. 20 (4), 699–708.
Bajgelman, M.C., Strauss, B.E., 2006. The DU145 human prostate carcinoma cell line
harbors a temperature-sensitive allele of p53. Prostate 66 (13), 1455–1462.
Bajgelman, M.C., Strauss, B.E., 2008. Development of an adenoviral vector with
robust expression driven by p53. Virology 371 (1), 8–13.
Barak, Y., Juven, T., Haffner, R., Oren, M., 1993. mdm2 expression is induced by wild
type p53 activity. EMBO J. 12 (2), 461–468.
Beckerman, R., Prives, C., 2010. Transcriptional regulation by p53. Cold Spring Harb.
Perspect. Biol. 2 (8), a000935.
Bensaad, K., Tsuruta, A., Selak, M.A., Vidal, M.N., Nakano, K., Bartrons, R., Gottlieb, E.,
Vousden, K.H., 2006. TIGAR, a p53-inducible regulator of glycolysis and
apoptosis. Cell 126 (1), 107–120.
Chuang, J.C., Sheu, G.T., Wang, P.C., Liao, F.T., Liu, W.S., Huang, C.F., Tseng, M.H., Wu,
M.F., 2012. Docetaxel and 5-ﬂuorouracil induce human p53 tumor suppressor
gene transcription via a short sequence at core promoter element. Toxicol. In
Vitro 26 (5), 678–685.
Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P.R., Gasco, M.,
Garrone, O., Crook, T., Ryan, K.M., 2006. DRAM, a p53-induced modulator of
autophagy, is critical for apoptosis. Cell 126 (1), 121–134.
Doman, R.K., Perez, M., Donato, N.J., 1999. JNK and p53 stress signaling cascades are
altered in MCF-7 cells resistant to tumor necrosis factor-mediated apoptosis. J.
Interferon Cytokine Res. 19 (3), 261–269.
Duan, D., Yue, Y., Yan, Z., Engelhardt, J.F., 2000. A new dual-vector approach to
enhance recombinant adeno-associated virus-mediated gene expression
through intermolecular cis activation. Nat. Med. 6 (5), 595–598.
el-Deiry, W.S., Harper, J.W., O'Connor, P.M., Velculescu, V.E., Canman, C.E., Jackman,
J., Pietenpol, J.A., Burrell, M., Hill, D.E., Wang, Y., et al., 1994. WAF1/CIP1 is
M.C. Bajgelman et al. / Virology 447 (2013) 166–171170
induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54 (5),
1169–1174.
el-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W., Vogelstein, B., 1992. Deﬁni-
tion of a consensus binding site for p53. Nat. Genet. 1 (1), 45–49.
el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D.,
Mercer, W.E., Kinzler, K.W., Vogelstein, B., 1993. WAF1, a potential mediator of
p53 tumor suppression. Cell 75 (4), 817–825.
Feng, L., Hollstein, M., Xu, Y., 2006. Ser46 phosphorylation regulates p53-dependent
apoptosis and replicative senescence. Cell Cycle 5 (23), 2812–2819.
Funk, W.D., Pak, D.T., Karas, R.H., Wright, W.E., Shay, J.W., 1992. A transcriptionally
active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12
(6), 2866–2871.
Hermeking, H., 2007. p53 enters the microRNA world. Cancer Cell 12 (5), 414–418.
Hildesheim, J., Bulavin, D.V., Anver, M.R., Alvord, W.G., Hollander, M.C., Vardanian,
L., Fornace Jr., A.J., 2002. Gadd45a protects against UV irradiation-induced skin
tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer
Res. 62 (24), 7305–7315.
Junttila, M.R., Evan, G.I., 2009. p53—a Jack of all trades but master of none. Nat. Rev.
Cancer 9 (11), 821–829.
Juven, T., Barak, Y., Zauberman, A., George, D.L., Oren, M., 1993. Wild type p53 can
mediate sequence-speciﬁc transactivation of an internal promoter within the
mdm2 gene. Oncogene 8 (12), 3411–3416.
Kern, S.E., Kinzler, K.W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., Vogelstein, B.,
1991. Identiﬁcation of p53 as a sequence-speciﬁc DNA-binding protein. Science
252 (5013), 1708–1711.
Kern, S.E., Pietenpol, J.A., Thiagalingam, S., Seymour, A., Kinzler, K.W., Vogelstein, B.,
1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science
256 (5058), 827–830.
Kim, W.H., Lee, J.W., Gao, B., Jung, M.H., 2005. Synergistic activation of JNK/SAPK
induced by TNF-alpha and IFN-gamma: apoptosis of pancreatic beta-cells via
the p53 and ROS pathway. Cell Signal. 17 (12), 1516–1532.
Klokov, D., Leskov, K., Araki, S., Zou, Y., Goetz, E.M., Luo, X., Willson, D., Boothman,
D.A., 2012. Low dose IR-induced IGF-1-sCLU expression: a p53-repressed
expression cascade that interferes with TGFbeta1 signaling to confer a pro-
survival bystander effect. Oncogene 32 (4), 479–490.
Leger, A., Le Guiner, C., Nickerson, M.L., Im, K.McGee, Ferry, N., Moullier, P., Snyder,
R.O., Penaud-Budloo, M., 2011. Adeno-associated viral vector-mediated trans-
gene expression is independent of DNA methylation in primate liver and
skeletal muscle. PLoS One 6 (6), e20881.
Leri, A., Claudio, P.P., Li, Q., Wang, X., Reiss, K., Wang, S., Malhotra, A., Kajstura, J.,
Anversa, P., 1998. Stretch-mediated release of angiotensin II induces myocyte
apoptosis by activating p53 that enhances the local renin-angiotensin system
and decreases the Bcl-2-to-Bax protein ratio in the cell. J. Clin. Invest. 101 (7),
1326–1342.
Leri, A., Fiordaliso, F., Setoguchi, M., Limana, F., Bishopric, N.H., Kajstura, J., Webster,
K., Anversa, P., 2000. Inhibition of p53 function prevents renin-angiotensin
system activation and stretch-mediated myocyte apoptosis. Am. J. Pathol. 157
(3), 843–857.
Li, H., Murphy, S.L., Giles-Davis, W., Edmonson, S., Xiang, Z., Li, Y., Lasaro, M.O., High,
K.A., Ertl, H.C., 2007. Pre-existing AAV capsid-speciﬁc CD8þ T cells are unable
to eliminate AAV-transduced hepatocytes. Mol. Ther. 15 (4), 792–800.
Liao, X.D., Wang, X.H., Jin, H.J., Chen, L.Y., Chen, Q., 2004. Mechanical stretch induces
mitochondria-dependent apoptosis in neonatal rat cardiomyocytes and G2/M
accumulation in cardiac ﬁbroblasts. Cell Res. 14 (1), 16–26.
Long, X., Boluyt, M.O., Hipolito, M.L., Lundberg, M.S., Zheng, J.S., O'Neill, L., Cirielli,
C., Lakatta, E.G., Crow, M.T., 1997. p53 and the hypoxia-induced apoptosis of
cultured neonatal rat cardiac myocytes. J. Clin. Invest. 99 (11), 2635–2643.
Lowe, S.W., Ruley, H.E., Jacks, T., Housman, D.E., 1993. p53-dependent apoptosis
modulates the cytotoxicity of anticancer agents. Cell 74 (6), 957–967.
Michalovitz, D., Halevy, O., Oren, M., 1990. Conditional inhibition of transformation
and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62 (4),
671–680.
Olive, M., Eisenlohr, L., Flomenberg, N., Hsu, S., Flomenberg, P., 2002. The
adenovirus capsid protein hexon contains a highly conserved human CD4þ
T-cell epitope. Hum. Gene Ther. 13 (10), 1167–1178.
Palomeque, J., Chemaly, E.R., Colosi, P., Wellman, J.A., Zhou, S., Del Monte, F., Hajjar,
R.J., 2007. Efﬁciency of eight different AAV serotypes in transducing rat
myocardium in vivo. Gene Ther. 14 (13), 989–997.
Rashi-Elkeles, S., Elkon, R., Shavit, S., Lerenthal, Y., Linhart, C., Kupershtein, A.,
Amariglio, N., Rechavi, G., Shamir, R., Shiloh, Y., 2011. Transcriptional modula-
tion induced by ionizing radiation: p53 remains a central player. Mol. Oncol. 5
(4), 336–348.
Ravikumar, B., Sarkar, S., Davies, J.E., Futter, M., Garcia-Arencibia, M., Green-
Thompson, Z.W., Jimenez-Sanchez, M., Korolchuk, V.I., Lichtenberg, M., Luo,
S., Massey, D.C., Menzies, F.M., Moreau, K., Narayanan, U., Renna, M., Siddiqi, F.
H., Underwood, B.R., Winslow, A.R., Rubinsztein, D.C., 2010. Regulation of
mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 90
(4), 1383–1435.
Rivera, V.M., Ye, X., Courage, N.L., Sachar, J., Cerasoli Jr., F., Wilson, J.M., Gilman, M.,
1999. Long-term regulated expression of growth hormone in mice after
intramuscular gene transfer. Proc. Natl. Acad. Sci. USA 96 (15), 8657–8662.
Sano, M., Minamino, T., Toko, H., Miyauchi, H., Orimo, M., Qin, Y., Akazawa, H.,
Tateno, K., Kayama, Y., Harada, M., Shimizu, I., Asahara, T., Hamada, H., Tomita,
S., Molkentin, J.D., Zou, Y., Komuro, I., 2007. p53-induced inhibition of Hif-1
causes cardiac dysfunction during pressure overload. Nature 446 (7134),
444–448.
Schambach, A., Wodrich, H., Hildinger, M., Bohne, J., Krausslich, H.G., Baum, C.,
2000. Context dependence of different modules for posttranscriptional
enhancement of gene expression from retroviral vectors. Mol. Ther. 2 (5),
435–445.
Sinthupibulyakit, C., Ittarat, W., St. Clair, W.H., St. Clair, D.K., 2010. p53 Protects lung
cancer cells against metabolic stress. Int. J. Oncol. 37 (6), 1575–1581.
Strauss, B.E., Bajgelman, M.C., Costanzi-Strauss, E., 2005. A novel gene transfer
strategy that combines promoter and transgene activities for improved tumor
cell inhibition. Cancer Gene Ther. 12 (12), 935–946.
Strauss, B.E., Costanzi-Strauss, E., 2004. pCLPG: a p53-driven retroviral system.
Virology 321 (2), 165–172.
Strauss, B.E., Patricio, J.R., de Carvalho, A.C., Bajgelman, M.C., 2006. A lentiviral
vector with expression controlled by E2F-1: a potential tool for the study and
treatment of proliferative diseases. Biochem. Biophys. Res. Commun. 348 (4),
1411–1418.
Sutton, T.A., Wilkinson, J., Mang, H.E., Knipe, N.L., Plotkin, Z., Hosein, M., Zak, K.,
Wittenborn, J., Dagher, P.C., 2008. p53 regulates renal expression of HIF-1
{alpha} and pVHL under physiological conditions and after ischemia-
reperfusion injury. Am. J. Physiol. Renal Physiol. 295 (6), F1666–F1677.
Vordermark, D., Shibata, T., Brown, J.M., 2001. Green ﬂuorescent protein is a
suitable reporter of tumor hypoxia despite an oxygen requirement for chro-
mophore formation. Neoplasia 3 (6), 527–534.
Wang, S., El-Deiry, W.S., 2003. Requirement of p53 targets in chemosensitization of
colonic carcinoma to death ligand therapy. Proc. Natl. Acad. Sci. USA 100 (25),
15095–15100.
Wang, W., Ho, W.C., Dicker, D.T., MacKinnon, C., Winkler, J.D., Marmorstein, R., El-
Deiry, W.S., 2005. Acridine derivatives activate p53 and induce tumor cell death
through Bax. Cancer Biol. Ther. 4 (8), 893–898.
Wang, W., Kim, S.H., El-Deiry, W.S., 2006. Small-molecule modulators of p53 family
signaling and antitumor effects in p53-deﬁcient human colon tumor xeno-
grafts. Proc. Natl. Acad. Sci. USA 103 (29), 11003–11008.
Worgall, S., Wolff, G., Falck-Pedersen, E., Crystal, R.G., 1997. Innate immune
mechanisms dominate elimination of adenoviral vectors following in vivo
administration. Hum. Gene Ther. 8 (1), 37–44.
Xavier-Neto, J., Pereira, A.C., Motoyama, A.H., Krieger, J.E., 1998. A luciferase-
engineered cell line for study of cAMP regulation in endothelial cells. Am. J.
Physiol. 275 (1 Pt 1), C75–C81.
Yan, C., Lu, D., Hai, T., Boyd, D.D., 2005. Activating transcription factor 3, a stress
sensor, activates p53 by blocking its ubiquitination. EMBO J. 24 (13),
2425–2435.
Zhang, W., Guo, X.Y., Hu, G.Y., Liu, W.B., Shay, J.W., Deisseroth, A.B., 1994. A
temperature-sensitive mutant of human p53. EMBO J. 13 (11), 2535–2544.
M.C. Bajgelman et al. / Virology 447 (2013) 166–171 171
